The Food and Drug Administration announced that Philips recalled the software following 109 reported injuries and two reported deaths.

The FDA announced today that a Philips (NYSE: PHG) + recall involving remote cardiac monitoring software is Class I, its most serious recall designation. On Dec. 18, 2024, Philips and its ...

The FDA is elevating a recall from Philips related to one of its wearable outpatient heart monitors, used to help detect ...

Advancements and Projections in the Global Cardiac Rhythm Management Devices Market: Insights, Trends, Opportunities, and ...

Investment firm Bridgefield Capital will buy the segment, which includes cardiac resuscitation and emergency care devices, ...

Philips’ application software for outpatient monitoring is used to analyze, display and report symptomatic and asymptomatic cardiac events in ECG data received from devices. The data is then sent to ...

Some electrocardiogram events, such as atrial fibrillation or abnormally rapid heartbeats, over two years were not reviewed by healthcare professionals due to a data routing issue.

Philips' smart systems and intelligent software showcased at Arab Health 2025 is developed to enable predictability, collaboration, precision, and integration to deliver better care for more people ...

The U.S. Food and Drug Administration (FDA) announced on Jan. 13 that Philips is correcting the Monitoring Service Application used with Mobile Cardiac Telemetry Monitoring as some electrocardiogram ...

Philips, a global leader in health technology, is unveiling its latest healthcare innovations at Arab Health 2025 in Dubai.